Cardiovascular drugs may not be associated with poor COVID-19 outcomes
Objectives:
Are cardiovascular drugs associated with poor COVID-19 outcomes?
Study design:
This review article included 390 studies.
Results and conclusions:
The investigators found the most-reported drugs were angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) with ACEI/ARB exposure having borderline association with confirmed COVID-19 infection [OR = 1.14, 95% CI = 1.00 to 1.31].